These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 38650367)

  • 1. Histopathological tumour microenvironment score independently predicts outcome in primary operable colorectal cancer.
    Hatthakarnkul P; Pennel K; Alexander P; van Wyk H; Roseweir A; Inthagard J; Hay J; Andersen D; Maka N; Park J; Roxburgh C; Thuwajit C; McMillan D; Edwards J
    J Pathol Clin Res; 2024 May; 10(3):e12374. PubMed ID: 38650367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The relationship between tumour budding, the tumour microenvironment and survival in patients with primary operable colorectal cancer.
    van Wyk HC; Park JH; Edwards J; Horgan PG; McMillan DC; Going JJ
    Br J Cancer; 2016 Jul; 115(2):156-63. PubMed ID: 27299960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Relationship Between Tumor Budding, Tumor Microenvironment, and Survival in Patients with Primary Operable Colorectal Cancer.
    van Wyk HC; Roseweir A; Alexander P; Park JH; Horgan PG; McMillan DC; Edwards J
    Ann Surg Oncol; 2019 Dec; 26(13):4397-4404. PubMed ID: 31605345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The relationship between tumour stroma percentage, the tumour microenvironment and survival in patients with primary operable colorectal cancer.
    Park JH; Richards CH; McMillan DC; Horgan PG; Roxburgh CSD
    Ann Oncol; 2014 Mar; 25(3):644-651. PubMed ID: 24458470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Glasgow Microenvironment Score: an exemplar of contemporary biomarker evolution in colorectal cancer.
    Knight K; Bigley C; Pennel K; Hay J; Maka N; McMillan D; Park J; Roxburgh C; Edwards J
    J Pathol Clin Res; 2024 Jul; 10(4):e12385. PubMed ID: 38853386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumour invasiveness, the local and systemic environment and the basis of staging systems in colorectal cancer.
    Park JH; van Wyk H; Roxburgh CSD; Horgan PG; Edwards J; McMillan DC
    Br J Cancer; 2017 May; 116(11):1444-1450. PubMed ID: 28427085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of a tumor microenvironment-based prognostic score in primary operable colorectal cancer.
    Park JH; McMillan DC; Powell AG; Richards CH; Horgan PG; Edwards J; Roxburgh CS
    Clin Cancer Res; 2015 Feb; 21(4):882-8. PubMed ID: 25473000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined epithelial marker analysis of tumour budding in stage II colorectal cancer.
    Slik K; Blom S; Turkki R; Välimäki K; Kurki S; Mustonen H; Haglund C; Carpén O; Kallioniemi O; Korkeila E; Sundström J; Pellinen T
    J Pathol Clin Res; 2019 Jan; 5(1):63-78. PubMed ID: 30358171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The relationship between the tumour stroma percentage, clinicopathological characteristics and outcome in patients with operable ductal breast cancer.
    Gujam FJ; Edwards J; Mohammed ZM; Going JJ; McMillan DC
    Br J Cancer; 2014 Jul; 111(1):157-65. PubMed ID: 24874480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The association between markers of tumour cell metabolism, the tumour microenvironment and outcomes in patients with colorectal cancer.
    Roseweir AK; Clark J; McSorley ST; vanWyk HC; Quinn JA; Horgan PG; McMillan DC; Park JH; Edwards J
    Int J Cancer; 2019 May; 144(9):2320-2329. PubMed ID: 30521130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumour budding is associated with the mesenchymal colon cancer subtype and RAS/RAF mutations: a study of 1320 colorectal cancers with Consensus Molecular Subgroup (CMS) data.
    Trinh A; Lädrach C; Dawson HE; Ten Hoorn S; Kuppen PJK; Reimers MS; Koopman M; Punt CJA; Lugli A; Vermeulen L; Zlobec I
    Br J Cancer; 2018 Nov; 119(10):1244-1251. PubMed ID: 30385823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microenvironment, systemic inflammatory response and tumor markers considering consensus molecular subtypes of colorectal cancer.
    Jakab A; Patai ÁV; Darvas M; Tormássi-Bély K; Micsik T
    Pathol Oncol Res; 2024; 30():1611574. PubMed ID: 38645565
    [No Abstract]   [Full Text] [Related]  

  • 13. Prognostic effects of histology-based tumour microenvironment scores in resected distal bile duct cancer.
    Hwang HW; Kim JY; Lee SE; Choi YS; Hong SH; Lee TJ; Kim MK; Park ES; Hong SA
    Histopathology; 2020 Sep; 77(3):402-412. PubMed ID: 32473032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utility of Glasgow Microenvironment Score as a prognostic tool in colorectal carcinoma.
    Ahuja M; Dwarak A; Mallya V; Mandal S; Tomar R; Khurana N; Lal P; Singh K
    J Cancer Res Ther; 2023 Apr; 19(Supplement):S172-S176. PubMed ID: 37147995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor Budding in Colorectal Carcinoma Showing a Paradoxical Mitotic Index (Via PHH3) With Possible Association to the Tumor Stromal Microenvironment.
    Hacking S; Sajjan S; Angert M; Ebare K; Jin C; Chavarria H; Kataria N; Zhang L; Cho M; Thomas R; Lee L; Nasim M
    Appl Immunohistochem Mol Morphol; 2020 Sep; 28(8):627-634. PubMed ID: 31567276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peritumoral tertiary lymphoid structure and tumor stroma percentage predict the prognosis of patients with non-metastatic colorectal cancer.
    Wang Q; Shen X; An R; Bai J; Dong J; Cai H; Zhu H; Zhong W; Chen W; Liu A; Du J
    Front Immunol; 2022; 13():962056. PubMed ID: 36189233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The relationship between phosphorylation status of focal adhesion kinases, molecular subtypes, tumour microenvironment and survival in patients with primary operable ductal breast cancer.
    Andisha NM; McMillan DC; Gujam FJA; Roseweir A; Edwards J
    Cell Signal; 2019 Aug; 60():91-99. PubMed ID: 30981841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Glasgow Microenvironment Score and risk and site of recurrence in TNM I-III colorectal cancer.
    Alexander PG; van Wyk HC; Pennel KAF; Hay J; McMillan DC; Horgan PG; Roxburgh CSD; Edwards J; Park JH
    Br J Cancer; 2023 Feb; 128(4):556-567. PubMed ID: 36476660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An immune, stroma, and epithelial-mesenchymal transition-related signature for predicting recurrence and chemotherapy benefit in stage II-III colorectal cancer.
    Cai D; Wang W; Zhong ME; Fan D; Liu X; Li CH; Huang ZP; Zhu Q; Lv MY; Hu C; Duan X; Wu XJ; Gao F
    Cancer Med; 2023 Apr; 12(7):8924-8936. PubMed ID: 36629124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Back to the future: routine morphological assessment of the tumour microenvironment is prognostic in stage II/III colon cancer in a large population-based study.
    Hynes SO; Coleman HG; Kelly PJ; Irwin S; O'Neill RF; Gray RT; McGready C; Dunne PD; McQuaid S; James JA; Salto-Tellez M; Loughrey MB
    Histopathology; 2017 Jul; 71(1):12-26. PubMed ID: 28165633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.